Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 6/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462324 | 0.86 | GRIK1 (0.82) | GRIK1MTORMPOHTTRAB9A | |
| SCHEMBL6440422 | 0.85 | GRIK1 (0.62) | GRIK1MTOREPHX2MPOBAZ1A | |
| SCHEMBL6438522 | 0.85 | GRIK1 (0.81) | GRIK1EPHX2MPOMEN1KMT2A | |
| SCHEMBL5809373 | 0.81 | EPHX2 (0.85) | MTOREPHX2BAZ1AHTTRAB9A | |
| SCHEMBL22524990 | 0.79 | KCNK2 (0.59) | GRIK1MPORAB9ANPC1KMT2A | |
| SCHEMBL5468541 | 0.78 | GRIK1 (0.81) | GRIK1MPOHTTRAB9AMEN1 | |
| SCHEMBL6439621 | 0.78 | GRIK1 (0.63) | GRIK1MPOHTTRAB9ANPC1 | |
| SCHEMBL6430905 | 0.77 | GRIK1 (1.00) | GRIK1MEN1KMT2A | |
| SCHEMBL28729179 | 0.77 | EPHX2 (1.00) | MTOREPHX2BAZ1AHTTRAB9A | |
| SCHEMBL11003408 | 0.77 | EPHX2 (1.00) | MTOREPHX2BAZ1AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1514867-A2 | Substituted phenyl derivatives, their preparation and use | NeuroSearch A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-6706749-B2 | CHLORIDE CHANNEL BLOCKERS; USEFUL IN THE TREATMENT OF SICKLE CELL ANAEMIA, BRAIN EDEMA FOLLOWING ISCAEMIA OR TUMORS, DIARRHEA, HYPERTENSION, BONE METABOLIC DISORDERS, OSTEOCLAST ASSOCIATED DISODERS; SUBSTITUTED BIPHENYL CONTAINING NITROGEN | NEUROSEARCH A/S (DK) | 2004-03-16 | — | — | US | disclosed |
| US-6696475-B2 | N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS | NEUROSEARCH A/S (DK) | 2004-02-24 | — | — | US | disclosed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| US-20020032210-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032210-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNB2, KCNH2 | GRIK1 1018/4885MTOR 2862/4885EPHX2 2676/4885 |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNH2, KCNJ2 | GRIK1 745/4885MTOR 2834/4885EPHX2 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.